← Back to Search

Behavioural Intervention

Gamma Frequency Stimulation for Down Syndrome

N/A
Recruiting
Led By Li-Huei Tsai, PhD
Research Sponsored by Massachusetts Institute of Technology
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Subject must have a clinically confirmed diagnosis of Down Syndrome (karyotypes optional). Individuals with mosaic Down syndrome will be excluded.
If subject is deemed to not have capacity to sign the informed consent, he/she will need a legally authorized representative to provide surrogate consent.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and immediately after the completion of the stimulation
Awards & highlights

Study Summary

This trial is testing a non-invasive way to remove toxic proteins from the brain in people with Down Syndrome, which may also improve memory.

Who is the study for?
This trial is for adults aged 25-65 with Down Syndrome, who are medically stable and have not changed medications in the last 3 months. They must be able to give consent or have a guardian do so. Excluded are those with recent strokes, migraines, untreated ADHD, certain medication use (like Wellbutrin), significant psychiatric risks, behavioral issues affecting protocol adherence, active medical implants, severe sensory impairments, pregnancy, autism co-diagnosis or recent seizures.Check my eligibility
What is being tested?
The study tests a non-invasive GENUS device that uses light and sound to stimulate the brain. It aims to improve cognitive function by removing toxic proteins associated with Alzheimer's Disease risk in people with Down Syndrome. Participants will undergo EEGs during stimulation sessions to measure brain waves and assess safety and cognitive effects.See study design
What are the potential side effects?
While specific side effects aren't listed for this trial of the GENUS device using tactile vibration stimulation via light and sound; generally such interventions may cause discomfort like headaches or sensory overload but tend to be minimal.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with Down Syndrome, not the mosaic type.
Select...
If I can't consent, someone legally allowed will do it for me.
Select...
I am between 25 and 65 years old.
Select...
My medication has been stable for the last 3 months.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~immediately after the completion of stimulation
This trial's timeline: 3 weeks for screening, Varies for treatment, and immediately after the completion of stimulation for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Acoustic Stimulation
Incidence of Stimulation-Related Adverse Events
Other outcome measures
Changes in memory and cognitive performance after gamma frequency stimulation

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: Down Syndrome ExperimentalExperimental Treatment1 Intervention
Experimental arm within Down Syndrome participant group: exposure to active 40Hz stimulation for 30-60 minutes.
Group II: Cognitively Normal ExperimentalExperimental Treatment1 Intervention
Experimental arm within the cognitively normal control participant group: exposure to active 40Hz stimulation for 30-60 minutes.
Group III: Down Syndrome ShamPlacebo Group1 Intervention
Sham arm within the Down Syndrome participant group: exposure to control stimulation for 30-60 minutes.
Group IV: Cognitively Normal ShamPlacebo Group1 Intervention
Sham arm within the cognitively normal control participant group: exposure to control stimulation for 30-60 minutes.

Find a Location

Who is running the clinical trial?

Massachusetts Institute of TechnologyLead Sponsor
97 Previous Clinical Trials
12,729,927 Total Patients Enrolled
Li-Huei Tsai, PhDPrincipal InvestigatorMassachusetts Institute of Technology
3 Previous Clinical Trials
135 Total Patients Enrolled
Diane Chan, MD, PhDPrincipal InvestigatorMassachusetts Institute of Technology
2 Previous Clinical Trials
95 Total Patients Enrolled

Media Library

GENUS device (Behavioural Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05196984 — N/A
Down Syndrome Research Study Groups: Down Syndrome Experimental, Down Syndrome Sham, Cognitively Normal Experimental, Cognitively Normal Sham
Down Syndrome Clinical Trial 2023: GENUS device Highlights & Side Effects. Trial Name: NCT05196984 — N/A
GENUS device (Behavioural Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05196984 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this research endeavor include participants who are 45 years or older?

"Qualified applicants for this healthcare experiment must be between 25 and 65 years old. There are 382 trials designed to aid those under 18, while 988 clinical studies have been created with those over 65 in mind."

Answered by AI

Are any further participants being recruited for this research project?

"That is accurate. According to clinicaltrials.gov, this research project which was initially posted on December 6th 2021, is now actively searching for individuals to join the study. The trial requires 60 volunteers from one medical site."

Answered by AI

Am I eligible to take part in this research trial?

"This research is searching for 60 individuals with Down syndrome aged 25 to 65. To qualify, a patient must have been clinically diagnosed and should not possess mosaic Down syndrome. Additionally, karyotyping is optional but beneficial in the screening process."

Answered by AI

How many people can participate in this clinical experiment?

"Indeed, the clinicaltrials.gov website attests to the fact that this study has began participant recruitment; it was first published on December 6th 2021 and last modified on October 13th 2022. The trial necessitates 60 recruits from a single site."

Answered by AI
~4 spots leftby Jun 2024